{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:18Z","timestamp":1790096898159,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104775","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:29:58Z","timestamp":1787095798000},"page":"104775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient experience data as a methodological and strategic innovation in clinical trial design"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-9179","authenticated-orcid":false,"given":"Alice","family":"Vanneste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Jankelevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lukeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sinnaeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Adriaenssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104775_b0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hex.12852","article-title":"Patient and public involvement in medical performance processes: a systematic review","volume":"22","author":"Lalani","year":"2019","journal-title":"Health Expect"},{"key":"10.1016\/j.drudis.2026.104775_b0010","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.drudis.2026.104775_b0015","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.12454","article-title":"Patient involvement in health care decision making: a review","volume":"16","author":"Vahdat","year":"2014","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/j.drudis.2026.104775_b0020","article-title":"Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis","volume":"363","author":"Crocker","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104775_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41927-023-00327-w","article-title":"Patient and public involvement in research: a review of practical resources for young investigators","volume":"7","author":"Arumugam","year":"2023","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.drudis.2026.104775_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h809","article-title":"Avoidable waste of research related to inadequate methods in clinical trials","volume":"350","author":"Yordanov","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104775_b0035","unstructured":"European Medicines Agency. Reflection paper on patient experience data. Report No.: EMA\/CHMP\/PRAC\/148869\/2025 Contract No.: EMA\/CHMP\/PRAC\/148869\/2025. Accessed 5 January 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-patient-experience-data_en.pdf; 2025."},{"key":"10.1016\/j.drudis.2026.104775_b0040","unstructured":"U.S. Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. Updated 23 October 2025. Accessed 5 January 2026. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical."},{"key":"10.1016\/j.drudis.2026.104775_b0045","unstructured":"The PREFER Consortium. PREFER recommendations\u2014why, when and how to assess and use patient preferences in medical product decision-making. Accessed 7 January 2026. https:\/\/www.imi-prefer.eu\/w\/ip\/recommendations\/; 2022."},{"key":"10.1016\/j.drudis.2026.104775_b0050","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/2168479017706405","article-title":"Improving patient involvement in medicines research and development: a practical roadmap","volume":"51","author":"Geissler","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104775_b0055","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41581-022-00585-w","article-title":"Patient-centred clinical trial design","volume":"18","author":"Tong","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.drudis.2026.104775_b0060","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamacardio.2017.3606","article-title":"Incorporating patient and caregiver experiences into cardiovascular clinical trial design","volume":"2","author":"Collins","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.drudis.2026.104775_b0065","first-page":"129","article-title":"Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions","volume":"37","author":"Faulkner","year":"2023","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.drudis.2026.104775_b0070","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jval.2016.04.009","article-title":"Increasing patient involvement in drug development","volume":"19","author":"Lowe","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2026.104775_b0075","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jval.2019.12.005","article-title":"Integrating the voice of the patient into the medical device regulatory process using patient preference information","volume":"23","author":"Benz","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2026.104775_b0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cct.2004.09.003","article-title":"Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels","volume":"25","author":"Willke","year":"2004","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.drudis.2026.104775_b0085","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajmg.a.38629","article-title":"The art and science of choosing efficacy endpoints for rare disease clinical trials","volume":"176","author":"Cox","year":"2018","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.drudis.2026.104775_b0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.hfc.2012.09.002","article-title":"End points for comparative effectiveness research in heart failure","volume":"9","author":"Allen","year":"2013","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.drudis.2026.104775_b0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-11-83","article-title":"Potential of patient-reported outcomes as nonprimary endpoints in clinical trials","volume":"11","author":"Gnanasakthy","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.drudis.2026.104775_b0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.semradonc.2023.07.002","article-title":"Patient-reported outcomes in clinical trials: from an endpoint to an intervention in cancer care","volume":"33","author":"Narra","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.drudis.2026.104775_b0105","doi-asserted-by":"crossref","first-page":"e01","DOI":"10.15420\/cfr.2021.13","article-title":"Endpoints in heart failure drug development","volume":"8","author":"Hussain","year":"2022","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.drudis.2026.104775_b0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11897-017-0334-z","article-title":"Novel endpoints for heart failure clinical trials","volume":"14","author":"Hamo","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.drudis.2026.104775_b0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10194-008-0052-8","article-title":"Meeting patient expectations in migraine treatment: what are the key endpoints?","volume":"9","author":"Antonaci","year":"2008","journal-title":"J Headache Pain"},{"key":"10.1016\/j.drudis.2026.104775_b0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14712598.2020.1702020","article-title":"Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective","volume":"20","author":"Allen","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.drudis.2026.104775_b0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00115677-200008020-00004","article-title":"Recent developments for optimal end-points in rheumatoid arthritis clinical studies","volume":"8","author":"Molenaar","year":"2000","journal-title":"Dis Manage Health Outcomes"},{"key":"10.1016\/j.drudis.2026.104775_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045105","article-title":"SPIRIT-PRO extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials","volume":"11","author":"Calvert","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2026.104775_b0135","first-page":"1","article-title":"The evolution of clinical trials in metastatic breast cancer: design features and endpoints that matter","volume":"40","author":"Seidman","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.drudis.2026.104775_b0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/2168479016671559","article-title":"Patient voice in rare disease drug development and endpoints","volume":"51","author":"Deal","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104775_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002447","article-title":"Core outcome Set-STAndards for development: the COS-STAD recommendations","volume":"14","author":"Kirkham","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2026.104775_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002148","article-title":"Core Outcome Set-STAndards for reporting: the COS-STAR statement","volume":"13","author":"Kirkham","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2026.104775_b0155","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.117.026229","article-title":"Composite end points in clinical research: a time for reappraisal","volume":"135","author":"Armstrong","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2026.104775_b0160","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1093\/eurheartj\/ehae647","article-title":"The win ratio in cardiology trials: lessons learnt, new developments, and wise future use","volume":"45","author":"Pocock","year":"2024","journal-title":"Eur Heart J"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:16:08Z","timestamp":1790093768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001807"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104775","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient experience data as a methodological and strategic innovation in clinical trial design","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104775"}}